Brought to you by 
Replidyne closes $62.5mm Series D round
26 Oct 2012
Executive Summary
Anti-infective drug developer Replidyne raised $62.5mm with its Series D venture round led by new investors Duquesne Capital Management, HealthCare Investment, and MDS Life Sciences Technology II funds (managed by MDS Capital). Returning backers HealthCare Ventures, TPG Ventures, Morgenthaler Ventures, Perseus-Soros BioPharmaceutical Fund, Sequel Venture Partners, Temasek Holdings, and Quintiles also participated.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com